Vaxcyte to Present at the SVB Securities Global Biopharma Conference

Rhea-AI Summary

Vaxcyte, Inc. (Nasdaq: PCVX), a clinical-stage vaccine innovation company, will participate in a fireside chat at the SVB Securities Global Biopharma Conference on February 14, 2023, at 3:00 p.m. ET. The live presentation will be available via webcast on the company's website, with a replay accessible for 30 days post-conference. Vaxcyte focuses on engineering high-fidelity vaccines to combat bacterial diseases. Its lead candidate, VAX-24, is a 24-valent pneumococcal conjugate vaccine aimed at preventing invasive pneumococcal disease. The company employs advanced synthetic techniques to improve vaccine development efficiency.

SAN CARLOS, Calif., Feb. 07, 2023 (GLOBE NEWSWIRE) -- Vaxcyte, Inc. (Nasdaq: PCVX), a clinical-stage vaccine innovation company engineering high-fidelity vaccines to protect humankind from the consequences of bacterial diseases, today announced that Company management will participate in a fireside chat at the SVB Securities Global Biopharma Conference on Tuesday, February 14, 2023, at 3:00 p.m. ET / 12:00 p.m. PT.

A live webcast of the presentation can be accessed through the Investors & Media section of the Company’s website at http://investors.vaxcyte.com. A replay of the webcast will be available for approximately 30 days following the conference.

About Vaxcyte
Vaxcyte is a vaccine innovation company engineering high-fidelity vaccines to protect humankind from the consequences of bacterial diseases. The Company is developing broad-spectrum conjugate and novel protein vaccines to prevent or treat bacterial infectious diseases. Vaxcyte’s lead candidate, VAX-24, is a 24-valent, broad-spectrum, carrier-sparing pneumococcal conjugate vaccine (PCV) being developed for the prevention of invasive pneumococcal disease. Vaxcyte is re-engineering the way highly complex vaccines are made through modern synthetic techniques, including advanced chemistry and the XpressCF™ cell-free protein synthesis platform, exclusively licensed from Sutro Biopharma, Inc. Unlike conventional cell-based approaches, the Company’s system for producing difficult-to-make proteins and antigens is intended to accelerate its ability to efficiently create and deliver high-fidelity vaccines with enhanced immunological benefits. Vaxcyte’s pipeline also includes VAX-31, a 31-valent PCV candidate; VAX-A1, a prophylactic vaccine candidate designed to prevent Group A Strep infections; and VAX-PG, a therapeutic vaccine candidate designed to slow or stop the progression of periodontal disease. Vaxcyte is driven to eradicate or treat invasive bacterial infections, which have serious and costly health consequences when left unchecked. For more information, visit www.vaxcyte.com.

Contacts:
Jennifer Zibuda, Senior Director, Investor Relations
Vaxcyte, Inc.
860-729-8902
investors@vaxcyte.com

Janet Graesser, Vice President, Corporate Communications and Investor Relations
Vaxcyte, Inc.
917-685-8799
media@vaxcyte.com

FAQ

What is Vaxcyte's role in the biopharmaceutical industry?

Vaxcyte is a clinical-stage vaccine innovation company focused on developing high-fidelity vaccines to combat bacterial diseases.

When is Vaxcyte participating in the SVB Securities Global Biopharma Conference?

Vaxcyte will participate in the SVB Securities Global Biopharma Conference on February 14, 2023, at 3:00 p.m. ET.

How can I watch Vaxcyte's presentation at the conference?

The live webcast of Vaxcyte's presentation can be accessed through the Investors & Media section of their website.

What are Vaxcyte's main vaccine candidates?

Vaxcyte's main vaccine candidates include VAX-24, a 24-valent pneumococcal conjugate vaccine, and VAX-31, a 31-valent candidate, among others.

What is the ticker symbol for Vaxcyte?

The ticker symbol for Vaxcyte is PCVX, and it is listed on Nasdaq.